What We Do
European Thrombosis and Haemostasis Alliance
The European Thrombosis and Haemostasis Alliance (ETHA), representing 28 member organisations, advocates for prioritisation of thrombosis and haemostasis within EU health and patient safety strategies. By collaborating with EU bodies, regulators, MEPs, and stakeholders, ETHA advances research, education and clinical practices to improve patient care and raise awareness of bleeding and clotting disorders across Europe. Supported by the International Society on Thrombosis and Haemostasis (ISTH) through a Memorandum of Understanding.
OUR MISSION
The mission of the European Thrombosis and Haemostasis Alliance (ETHA) is to give the thrombosis and hemostasis community a voice and to drive prioritisation of thrombosis and hemostasis in the EU patient safety and research programs. With a united focus on raising awareness of bleeding and clotting disorders, ETHA stands together to work with the public as well as decision makers' to provide input into EU health and patient safety strategies.
ETHA is led by Mettine Bos, an Assistant Professor at the Leiden University Medical Center in The Netherlands.
ETHA CONSENSUS STATEMENT
To learn more about ETHA’s initial areas of priority, read its consensus statement, here.
WHAT WE DO
Our aim is to enhance the health outcomes of patients worldwide by promoting funding opportunities for research in thrombosis and hemostasis, while also leveraging education and awareness. To achieve this, we are building relationships with governments, inter-governmental agencies, and regulatory bodies to highlight the importance of thrombosis and hemostasis in promoting better health outcomes. We are also collaborating with the global thrombosis and hemostasis community, as well as other medical specialties with similar interests, to advance common agendas.
​
Our efforts involve educating policy makers about the burden of disease caused by thrombosis and the effective health interventions available. We also highlight pressing scientific challenges related to thrombosis and hemostasis that require continued funding. Our goal is to position the ETHA as an important voice and EU stakeholder in the field of non-communicable diseases.
